Bavarian Nordic sees 'huge potential' in cancer vaccine combos, CEO says

CEO Paul Chaplin told FiercePharma that Bavarian Nordic would be open to future partnerships under the right circumstances.

As interest in cancer vaccine combos surges, Bavarian Nordic is inclined to remain an independent vaccine company, according to CEO Paul Chaplin. That's because, he says, it's the “best and most fruitful way” to get the most out of the company's platform in a variety of disease targets.

Despite industrywide struggles in 2016, BN itself had a “great year” by raising capital and moving along its pipeline assets, Chaplin told FiercePharma.

Bavarian Nordic sees “huge potential” in cancer vaccine combos, Chaplin said, with Chief Medical Officer Chris Heery, M.D., adding that there’s an increased willingness around the industry to partner checkpoint inhibitors with vaccines. Bavarian Nordic is currently testing multiple combos with Bristol-Myers Squibb and plans to start new studies in “additional indications,” the helmsman said.

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

Immuno-oncology is “hot today, but we have been here for a long time and we have a large amount of experience in the field,” Chaplin said. Heery, who joined Bavarian Nordic as Chief Medical Officer in September from the National Cancer Institute, said it’s an “extremely exciting time” to be in I/O. He joined the company to work at an “inflection point at which we can actually see the effect of therapeutic cancer vaccines in patients.”

Elsewhere in its pipeline, the Danish biotech has made its way to the forefront in RSV, Chaplin said, after reporting positive phase 1 data for its own candidate and with the late-stage failure of a rival from Novavax. Bavarian Nordic has a “differentiated approach and one that I think will be successful in long run” in RSV, Chaplin said.

The company’s phase 2 RSV trial, which completed enrollment last month, should read out in the middle of this year.

Bavarian Nordic raised $100 million privately in 2016 after canceling its IPO due to market conditions, a fundraising effort Chaplin said demonstrates a “loyalty and belief” in the company’s pipeline and platform.

Aside from Bristol-Myers Squibb, Bavarian Nordic has partnered with Janssen to develop a therapeutic HPV vaccine, with the option for Janssen to license Bavarian Nordic's vaccine tech for two additional undisclosed infectious disease targets. The biotech could be open to future buys or partnerships if the situation were right, Chaplin said.

Suggested Articles

Three facts about how distributors are managing in-demand inventory.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.

Purdue has reached an $8 billion settlement with the U.S. government to settle criminal and civil charges for its role in the U.S. opioid crisis.